EFFECT OF SILYMARIN ON INTESTINAL ALKALINE PHOSPHATASE LEVEL IN A RAT MODEL OF TYPE 2 DIABETES MELLITUS: STREPTOZOTOCIN AND HIGH-FAT DIET TREATED WISTAR RATS

  • Lalitha V Department of Pharmacology, Nandha College of Pharmacy and Research Institute, Erode, Tamil Nadu, India.
  • Sivakumar T Department of Pharmacology, Nandha College of Pharmacy and Research Institute, Erode, Tamil Nadu, India.

Abstract

Objective: This research elucidated the role of silymarin on intestinal alkaline phosphatase (IAP) level in type 2 diabetic rats.

Methods: The type 2 diabetes mellitus was induced by a high-fat diet (HFD - 58% calories fat) for 2 weeks, and rats were intraperitoneally injected with streptozotocin (STZ) 35 mg/kg. Wistar rats were divided into four groups. Group I served as a non-diabetic (normal), Group II served as diabetic, Group III diabetic animals treated glibenclamide 600 μg/kg for 14 days, and Group IV diabetic animal treated with glibenclamide and silymarin 50 mg/kg/twice/d for 14 days. At the end of the study, blood glucose, lipid profile, and IAP level were measured.

Results: A significant decrease in IAP, elevated levels of blood glucose, and lipid profile was seen in diabetic rats when compared with normal. The silymarin treatment showed a significant increase in IAP level, a significant reduction in glucose and lipid profile than diabetic rats.

Conclusion: The present study concludes that silymarin treatment enhances the IAP levels which protect against hyperglycemia, hyperlipidemia, and vascular complications in diabetic rats.

Keywords: High-fat diet, Streptozotocin, Silymarin, Intestinal alkaline phosphatase.

Author Biography

Lalitha V, Department of Pharmacology, Nandha College of Pharmacy and Research Institute, Erode, Tamil Nadu, India.
Department of Pharmacoloy

References

1. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of Type 2 diabetes mellitus. J Clin Invest 1999;104:787-94.
2. Lebovitz HE. Diagnosis, classification, and pathogenesis of diabetes mellitus. J Clin Psychiatry 2001;62 Suppl 27:5-9.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37 Suppl 1:S81-90.
4. LeRoith D, Fonseca V, Vinik A. Metabolic memory in diabetes – focus on insulin. Diabetes Metab Res Rev 2005;21:85-90.
5. Abdullah N, Attia J, Oldmeadow C, Scott RJ, Holliday EG. The architecture of risk for Type 2 diabetes: Understanding Asia in the context of global findings. Int J Endocrinol 2014;2014:21.
6. Comelli MC, Mengs U, Schneider C, Prosdocimi M. Toward the definition of the mechanism of action of silymarin: Activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther 2007;6:120-9.
7. Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997;26:643-9.
8. Hassanein H, Abdel-Mohsen M, Shams K, Abdel-Azim N, Saleh M, Ehsan N, et al. Comparative analysis of the biological activity of Silybum marianum L. Food supplements available on the market: In vitro study. Int J Pharm Pharm Sci 2015;7:55-60.
9. Suh HJ, Cho SY, Kim EY, Choi HS. Blockade of lipid accumulation by silibinin in adipocytes and zebrafish. Chem Biol Interact 2015;227:53- 62.
10. Van Dongen JM, Kooyman J, Visser WJ, Holt SJ, Galjaard H. The effect of increased crypt cell proliferation on the activity and subcellular localization of esterases and alkaline phosphatase in the rat small intestine. Histochem J 1977;9:61-75.
11. Bates JM, Mittge E, Kuhlman J, Baden KN, Cheesman SE, Guillemin K, et al. Distinct signals from the microbiota promote different aspects of zebrafish gut differentiation. Dev Biol 2006;297:374-86.
12. Lallès JP. Intestinal alkaline phosphatase: Novel functions and protective effects. Nutr Rev 2014;72:82-94.
13. Jason F, David G. Intestinal alkaline phosphatase: A summary of its role in clinical disease. J Surg Res 2016;202:225-34.
14. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for Type 2 diabetes and pharmacological screening. Pharmacol Res 2005;52:313-20.
15. Takanori K, Tomoyuki T, Shuhachi K, Kei S. Facile preparation of rat intestinal mucosa for assay of mucosal enzyme activity. J Nutr Sci Vitaminol 1993;39:399-403.
16. Su-Yen G, Mark EC. The role of advanced Glycation end products in progression and complications of diabetes. J Clin Endocrinol Metabol 2008;93:1143-52.
17. Madhu SM. A high level of intestinal alkaline phosphatase is protective against Type2 diabetes mellitus irrespective of obesity. EBioMedicine 2015;2:2016-23.
18. Ghosh SS, Gehr TW, Ghosh S. Curcumin and chronic kidney disease (CKD): Major mode of action through stimulating endogenous intestinal alkaline phosphatase. Molecules 2014;19:20139-56.
19. Kaliannan K, Wang B, Li XY, Kim KJ, Kang JX. A host-microbiome interaction mediates the opposing effects of omega-6 and omega-3 fatty acids on metabolic endotoxemia. Sci Rep 2015;5:11276.
20. Mahmood A, Shao JS, Alpers DH. Rat enterocytes secrete SLPs containing alkaline phosphatase and cubilin in response to corn oil feeding. Am J Physiol Gastrointest Liver Physiol 2003;285:G433-41.
21. Bosisio E, Benelli C, Pirola O. Effect of the flavanolignans of silybum marianum L. On lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res 1992;25:147-54.
22. Wellington K, Adis BJ. Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs 2001;15:465-89.
23. Tasduq SA, Peerzada K, Koul S, Bhat R, Johri RK. Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin. Hepatol Res 2005;31:132-5.
24. Kiruthiga PV, Shafreen RB, Pandian SK, Devi KP. Silymarin protection against major reactive oxygen species released by environmental toxins: Exogenous H2O2 exposure in erythrocytes. Basic Clin Pharm Toxicol 2007;100:414-9.
25. Khazim K, Gorin Y, Cavaglieri RC, Abboud HE, Fanti P. The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo. Am J Physiol Renal Physiol 2013;305:F691- 700.
26. Mohamed EF, Amr N, Amira AE, Mona W. Antioxidant therapeutic actions of medical phytochemicals, silymarin, and silibinin on streptozotocin diabetic rats: First novel comparative assessment of structural recoveries of histological and ultrastructural changes on islets of Langerhans. Int J Pharm Pharm Sci 2016;8:69-76.
27. Sonoko N, Lei H, Aratr I, Hideaki H, David HA, Jose LM. Accelerated fat absorption in intestinal alkaline phosphatase knockout mice. Molecular Cellular Biol 2003;23:7525-30.
28. Kaliannan K, Hamarneh SR, Economopoulos KP, Nasrin Alam S, Moaven O, Patel P, et al. Intestinal alkaline phosphatase prevents metabolic syndrome in mice. Proc Natl Acad Sci U S A 2013;110:7003- 8.
Statistics
130 Views | 162 Downloads
Citatons
How to Cite
V, L., and S. T. “EFFECT OF SILYMARIN ON INTESTINAL ALKALINE PHOSPHATASE LEVEL IN A RAT MODEL OF TYPE 2 DIABETES MELLITUS: STREPTOZOTOCIN AND HIGH-FAT DIET TREATED WISTAR RATS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 11, Nov. 2018, pp. 304-6, doi:10.22159/ajpcr.2018.v11i11.28008.
Section
Original Article(s)